PFEPfizer
Price
+23%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growth steady, the market with it.
Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of 2025 Form 10-K biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Pfizer (PFE) reported revenue of $15.0B in Q2 2026 (quarter ended Jun 28, 2026), up 2.6% from the same quarter a year earlier. That came with a gross margin of 73% and net loss of $248M. For the full year FY2025, revenue was $62.6B (−1.6% year on year) and net income $7.77B. Its largest product in Q2 2026 was Eliquis at $2.42B, 16% of the disclosed total, just ahead of Vyndaqel at 11%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance.Earnings release · press release
- Jun 18, 2026On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s …Director or officer change · Form 8-K
- May 5, 2026Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $15.51BThe company’s own SEC segment disclosure.
- Eliquis$2.42B16%
- Vyndaqel$1.76B11%
- Prevnar Prevenar Family$1.34B9%
- Ibrance$1.06B7%
- All Other Hospital And Biosimilars$952.0M6%
- Other Primary Care Products$699.0M5%
- Other (32)$7.28B47%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
The closest names by size in the same industry